Table 1.
PD (n = 22) |
LHM (n =142) |
POEM (n =36) |
|||||
Factor | n | Summary | n | Summary | n | Summary | P value |
Age at diagnosis (yr) | 22 | 47.5 ± 17.0 | 142 | 45.8 ± 15.6 | 36 | 52.6 ± 17.2 | 0.078a |
Age at current treatment (yr) | 22 | 50.3 ± 17.9 | 142 | 46.5 ± 15.73 | 36 | 55.4 ± 16.82 | 0.013a |
Gender | 22 | 142 | 36 | 0.19c | |||
Female | 11 (50.0) | 71 (50.0) | 12 (33.3) | ||||
Male | 11 (50.0) | 71 (50.0) | 24 (66.7) | ||||
Ethnicity | 22 | 141 | 36 | 0.85d | |||
White | 17 (77.3) | 118 (83.7) | 31 (86.1) | ||||
Black | 4 (18.2) | 19 (13.5) | 4 (11.1) | ||||
Other | 1 (4.5) | 4 (2.8) | 1 (2.8) | ||||
BMI (kg/m2) | 22 | 27.1 ± 6.9 | 142 | 26.0 ± 5.13 | 36 | 29.1 ± 5.92 | 0.012a |
Achalasia sub-type | 14 | 120 | 34 | 0.023d | |||
Subtype 1 | 5 (35.7) | 30 (25.0) | 13 (38.2) | ||||
Subtype 2 | 6 (42.9) | 82 (68.3) | 18 (52.9) | ||||
Subtype 3 | 2 (14.3) | 1 (0.83) | 3 (8.8) | ||||
Achalasia variant | 1 (7.1) | 7 (5.8) | 0 (0.0) | ||||
Prior treatments | |||||||
Received any prior treatment | 22 | 15 (68.2) | 140 | 62 (44.3)3 | 36 | 26 (72.2)2 | 0.003c |
Months from last to current treatment | 14 | 17.7 [2.3, 87.5] | 54 | 6.3 [3.2,28.5] | 25 | 14.7 [6.4,20.2] | 0.29b |
Botulinium toxin injection | 22 | 1 (4.5) | 140 | 16 (11.4) | 36 | 8 (22.2) | 0.11c |
PD | 22 | 9 (40.9)2 | 140 | 19 (13.6)13 | 36 | 11 (30.6)2 | 0.002c |
LHM | 22 | 7 (31.8)2 | 140 | 1 (0.71)13 | 36 | 10 (27.8)2 | < 0.001c |
Botulinum toxin injection and regular endoscopic balloon dilation | 22 | 2 (9.1) | 140 | 1 (0.71) | 36 | 0 (0.0) | 0.050d |
Regular endoscopic balloon dilation | 22 | 3 (13.6) | 140 | 34 (24.3)3 | 36 | 2 (5.6)2 | 0.031c |
Significantly different from PD;
Significantly different from LHM;
Significantly different from POEM. Values presented as Mean ± SD, Median [P25, P75] or N (column %). P-value: a = ANOVA, b = Kruskal-Wallis test, c = Pearson's χ2 test, d = Fisher's Exact test. PD: Pneumatic dilation; LHM: Laparoscopic Heller myotomy; POEM: Peroral endoscopic myotomy.